NEWS & EVENTS

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics.

Catalent announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

The MSA encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU.

Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials.

Experts and speakers from Catalent and JLABS will be joined by speakers from Johnson & Johnson and Cardiff Advisory LLC.

OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.

Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.

Catalent today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.

The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply